Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of Reolysin (reovirus) in combination with carboplatin and paclitaxel in patients with advanced solid tumours (phase 1) and head and neck cancer (phase II).

Trial Profile

Phase I/II trial of Reolysin (reovirus) in combination with carboplatin and paclitaxel in patients with advanced solid tumours (phase 1) and head and neck cancer (phase II).

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary) ; Carboplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Oncolytics Biotech

Most Recent Events

  • 12 Sep 2017 Results (n=563) of pooled data from eight trial (NCI-GOG 0186H, NCI-8601, NCIC-CTG IND.213, REO011, REO015, REO016, REO018 and REO021) assessing the safety and tolerability of intravenous pelareorep in combination with chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
  • 20 Apr 2012 Status changed from active, no longer recruiting to completed based on presented results.
  • 07 Jun 2010 Updated survival results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top